EUCTR2006-003746-42-IT进行中（未招募）不适用
Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND
OSPEDALE ONCOLOGICO DI BARI0 个研究点目标入组 210 人开始时间: 2006年10月3日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologic diagnosis of kidney carcinoma 2. Presence of metastases and/or locally advanced primary tumour 3. Age 18 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Severe infections 2. Previous treatment with IL-2 3. Brain metastasis 4. Pregnancy
研究者
相似试验
进行中（未招募）
1 期
Stereotactic Body Radiation in combination with immunotherapy-chemotherapy in patients with Metastatic Non-Small Cell Lung Cancer.Patients with both squamous and nonsquamous metastatic non-small cell lung cancer (NSCLC) wild type in EGFR, KRAS, ALK and ROS1.MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002453-28-ITAZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA132
已完成
不适用
Immunological aspects of combined chemotherapy and immunotherapy with HPV16 E6/E7 Synthetic Long Peptide vaccination in patients with advanced cervical cancer.cancer of the cervix10038594cervical cancerNL-OMON36470eids Universitair Medisch Centrum18
已完成
1 期
Phase I study of Chemo-Immunotherapy in patients with relapsed and refractory head and neck carcinomaHead and neck squamous cell carcinomaJPRN-UMIN000003725niversity of Yamanashi, Faculty of Medicine10
进行中（未招募）
不适用
Randomised Study Comparing an Immuno-Chemotherapy with 6 Cycles of the Monoclonal anti-CD20 Antibody Rituximab in Combination with 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, both with or without consolidating Radiotherapy of Large Tumour Masses (≥ 7.5 cm) and/or Extranodal Involvement in Patients with Aggressive CD20+ B-Cell Lymphoma Aged 18 to 60 Years with Age-adjusted IPI=1 (all) or IPI=0 with Bulky Disease (≥ 7.5 cm) - UNFOLDEREUCTR2005-005218-19-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI1,072
进行中（未招募）
1 期
Randomised Study Comparing an Immuno-Chemotherapy with 6 Cyclesof the Monoclonal anti-CD20 Antibody Rituximab in Combination with6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine,and Prednisone) at 21-day Intervals or 14-day Intervals, both with or withoutconsolidating Radiotherapy of Large Tumour Masses (= 7.5 cm) and/orExtranodal involvement in Patients with Aggressive CD20+ B-Cell LymphomaAged 18 to 60 Years with Age-adjusted IPI=1 (all) or IPI=0 withBulky Disease (= 7.5 cm) Short Title: UNFOLDER 21/14 Study - UNFOLDER 21/14 studyPatients with untreated aggressive CD20+ Non-Hodgkin’s Lymphoma aged 18 to 60 years without major accompanying diseases with IPI= 1 (all) or IPI= 0 and bulky disease (=7.5cmEUCTR2005-005218-19-DKGerman High Grade Non-Hodgkin's Lymphoma group1,072